Joint Ventures and Other Equity Method Affiliates (Tables)

9 Months Ended

Sep. 30, 2012

Equity Income from Affiliates

Equity income from affiliates reflects the performance of the Company’s joint ventures and other equity method affiliates and was comprised of the following:

	Three Months Ended     September 30,				Nine Months Ended     September 30,
($ in millions)	2012		2011		2012		2011
AstraZeneca LP	$	134	$	141	$	387	$	318
Other (1)		24		20		23		36
	$	158	$	161	$	410	$	354

⁽¹⁾  Includes results from Sanofi Pasteur MSD.

Summarized Financial Information for Azlp

Summarized financial information for AZLP is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2012		2011		2012		2011
Sales	$	1,232	$	1,124	$	3,424	$	3,460
Materials and production costs		561		464		1,520		1,524
Other expense, net		204		357		936		1,004
Income before taxes (1)	$	467	$	303	$	968	$	932

⁽¹⁾  Merck’s partnership returns from AZLP are generally contractually determined and are not based on a percentage of income from AZLP, other than with respect to Merck’s 1% limited partnership interest.